Lower-Dose DMPA

Product Overview

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Injectable

Duration Type: Long-acting

Description: A single subcutaneous injection of medroxyprogesterone acetate injectable suspension, (dose between 45mg - 105mg), currently approved for IM use, every 3 months

Updated date: May 30, 2018

Vertical Tabs


Project Phase: Late Development

Project Stage: Phase I

Began discovery in: 2013

Status Details:
  • Currently in recruitment and follow up of Phase I study.

Download Product Report